Cargando…

Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors

BACKGROUND: Malignant tumors of the musculoskeletal system, especially osteosarcoma, Ewing sarcoma and rhabdomyosarcoma, pose a major threat to the lives and health of adolescents and children. Current treatments for musculoskeletal tumors mainly include surgery, chemotherapy, and radiotherapy. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei, Wang, Shubin, Lin, Binhui, Zhang, Wei, Ji, Guangrong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866880/
https://www.ncbi.nlm.nih.gov/pubmed/33546657
http://dx.doi.org/10.1186/s12891-021-04020-2
_version_ 1783648176094314496
author Liu, Wei
Wang, Shubin
Lin, Binhui
Zhang, Wei
Ji, Guangrong
author_facet Liu, Wei
Wang, Shubin
Lin, Binhui
Zhang, Wei
Ji, Guangrong
author_sort Liu, Wei
collection PubMed
description BACKGROUND: Malignant tumors of the musculoskeletal system, especially osteosarcoma, Ewing sarcoma and rhabdomyosarcoma, pose a major threat to the lives and health of adolescents and children. Current treatments for musculoskeletal tumors mainly include surgery, chemotherapy, and radiotherapy. The problems of chemotherapy resistance, poor long-term outcome of radiotherapy, and the inherent toxicity and side effects of chemical drugs make it extremely urgent to seek new treatment strategies. MAIN TEXT: As a potent gene editing tool, the rapid development of CRISPR/Cas9 technology in recent years has prompted scientists to apply it to the study of musculoskeletal tumors. This review summarizes the application of CRISPR/Cas9 technology for the treatment of malignant musculoskeletal tumors, focusing on its essential role in the field of basic research. CONCLUSION: CRISPR, has demonstrated strong efficacy in targeting tumor-related genes, and its future application in the clinical treatment of musculoskeletal tumors is promising.
format Online
Article
Text
id pubmed-7866880
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78668802021-02-08 Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors Liu, Wei Wang, Shubin Lin, Binhui Zhang, Wei Ji, Guangrong BMC Musculoskelet Disord Review BACKGROUND: Malignant tumors of the musculoskeletal system, especially osteosarcoma, Ewing sarcoma and rhabdomyosarcoma, pose a major threat to the lives and health of adolescents and children. Current treatments for musculoskeletal tumors mainly include surgery, chemotherapy, and radiotherapy. The problems of chemotherapy resistance, poor long-term outcome of radiotherapy, and the inherent toxicity and side effects of chemical drugs make it extremely urgent to seek new treatment strategies. MAIN TEXT: As a potent gene editing tool, the rapid development of CRISPR/Cas9 technology in recent years has prompted scientists to apply it to the study of musculoskeletal tumors. This review summarizes the application of CRISPR/Cas9 technology for the treatment of malignant musculoskeletal tumors, focusing on its essential role in the field of basic research. CONCLUSION: CRISPR, has demonstrated strong efficacy in targeting tumor-related genes, and its future application in the clinical treatment of musculoskeletal tumors is promising. BioMed Central 2021-02-05 /pmc/articles/PMC7866880/ /pubmed/33546657 http://dx.doi.org/10.1186/s12891-021-04020-2 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Liu, Wei
Wang, Shubin
Lin, Binhui
Zhang, Wei
Ji, Guangrong
Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors
title Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors
title_full Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors
title_fullStr Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors
title_full_unstemmed Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors
title_short Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors
title_sort applications of crispr/cas9 in the research of malignant musculoskeletal tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866880/
https://www.ncbi.nlm.nih.gov/pubmed/33546657
http://dx.doi.org/10.1186/s12891-021-04020-2
work_keys_str_mv AT liuwei applicationsofcrisprcas9intheresearchofmalignantmusculoskeletaltumors
AT wangshubin applicationsofcrisprcas9intheresearchofmalignantmusculoskeletaltumors
AT linbinhui applicationsofcrisprcas9intheresearchofmalignantmusculoskeletaltumors
AT zhangwei applicationsofcrisprcas9intheresearchofmalignantmusculoskeletaltumors
AT jiguangrong applicationsofcrisprcas9intheresearchofmalignantmusculoskeletaltumors